CClinicalTrials.gg
CompletedNCT06173804RESILIENTUpdated Jun 23, 2026

Multilevel Lifestyle Intervention to Improve Physical Function in Older Adults With Type 2 Diabetes

An interventional study of Adapted Look Ahead Lifestyle Intervention in Type 2 Diabetes, sponsored by The University of Texas Health Science Center at San Antonio. Completed at 1 site in United States. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-06-23.

Sponsored by The University of Texas Health Science Center at San Antonio · Not applicable, Interventional, and Health services research

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
60 Years and older
Sex
All
01

Study summary

The purpose of this study is to explore strategies to effectively implement senior-center-based multilevel lifestyle interventions adapted from evidence-based lifestyle interventions to promote physical function and quality of life in diverse older adults with Type 2 Diabetes (T2D).

Read the detailed description

Aim 1: Work with community stakeholders including individuals with T2D, family members, and senior center staff to adapt evidence-based lifestyle interventions, and develop implementation strategies.

Aim 2: Conduct a senior-center-based 6-month pre- and post-pilot study and collect recruitment, enrollment, retention rate, fidelity, program satisfaction and experience, and stakeholder acceptance using quantitative and qualitative data.

Aim 3: Assess the preliminary health-related responses to the intervention in older adults with T2D in the 6-month trial.

02

Conditions studied

  • Type 2 Diabetes

Keywords

  • Evidence based lifestyle intervention
  • Older Adults
  • Physical Function
  • Glycemic control
03

In context

Diabetes Mellitus, Type 2

9,359 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,318 are open to participants now.

This study's enrollment of 20 is below the median of 80 across 7,525 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

The University of Texas Health Science Center at San Antonio is the lead sponsor of 435 studies on the registry; 88 are open to participants now.

Of its 62 completed or terminated interventional studies of FDA-regulated products, 31 (50%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Adults aged ≥60 years
  2. Self-reported T2D diagnosis with verification from a health report
  3. Live within the census tract of the selected senior center, or a member of the senior center
  4. No significant cognitive impairment as defined by MMSE (score≥20) (46) which may influence diabetes self-management
  5. Can speak and understand either English or Spanish
  6. Agree to participate in the study procedures

Exclusion criteria

Exclusion Criteria:

  1. Severe chronic conditions without physician's permission to participate (e.g., severe heart disease and end-stage renal disease);
  2. Unwillingness to sign the consent form; and
  3. Enrollment in other diabetes management programs
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Lifestyle intervention group

    The study team will assess improvements in physical function assessed by the short physical performance battery and other health-related measures (diabetes knowledge, self-efficacy, social support, physical activity, diet consumption, HbA1c, and quality of life).

    Other: Adapted Look Ahead Lifestyle Intervention

Interventions

  • OtherAdapted Look Ahead Lifestyle Intervention

    Participants will be educated about improving healthy lifestyles involving physical activity and healthy eating to improve physical function and improve glycemic control.

    Also known as: Multilevel Lifestyle Intervention

06

What researchers measure

Primary outcomes

  1. Feasibility of conducting study

    Feasibility refers to how feasible to conduct the study. In this study, feasibility will be assessed by data such as participant recruitment, enrollment, education session attendance, and retention rate.

    Time frame: Baseline, 3, 6, and 12 months

  2. Acceptability

    Acceptability refers to how well an intervention will be received by the target population and the extent to which an intervention might meet the needs of the target population. Acceptability will be assessed through qualitative interview with participants to explore their experience, and perceptions with the intervention.

    Time frame: Baseline, 3, 6, and 12 months

Secondary outcomes

  1. Body Weight

    Measured in pounds with participant in light clothes and without shoes

    Time frame: Baseline, 3, 6, and 12 months

  2. Systolic Blood Pressure

    Sitting blood pressure will be measured after at least five minutes of rest.

    Time frame: Baseline, 3, 6, and 12 months

  3. Diastolic Blood Pressure

    Sitting blood pressure will be measured after at least five minutes of rest.

    Time frame: Baseline, 3, 6, and 12 months

  4. Short Physical Performance Battery (SPPB)

    The SPPB is a series of physical tests used to assess a person's lower extremity function. SPPB scores range from zero to 12 possible points. A higher score indicated better physical performance.

    Time frame: Baseline, 3, 6, and 12 months

  5. Grip Strength

    Grip strength will be measured in both hands, and the dominant hand will be recorded.

    Time frame: Baseline, 3, 6, and 12 months

  6. Glycated Hemoglobin (HbA1c)

    HbA1c is a blood test that is used to assess and monitor the average level of glucose over the past two to three months.

    Time frame: Baseline, 3, 6, and 12 months

  7. Lipid profile

    It is a blood test that measures the levels of fats and fatty substances in the blood. The following measurements in the profile will be assessed: cholesterol, LDL (low-density lipoprotein) cholesterol, HDL (high-density lipoprotein) cholesterol, and triglycerides.

    Time frame: Baseline, 3, 6, and 12 months

  8. IPAQ-12

    This scale contains 12 items that are a self-reported measure of physical activity. Scores are typically expressed in minutes per week. Higher scores indicate higher levels of physical activity, whereas lower scores suggest sedentary or low activity levels.

    Time frame: Baseline, 3, 6, and 12 months

  9. MoCA

    MoCA is a 30-point questionnaire that tests various cognitive domains, including memory, attention, language, abstraction, executive functions, visual skills, calculation, and orientation. The score ranges from 0-30, and higher score indicates better cognitive function.

    Time frame: Baseline, 3, 6, and 12 months

07

Study locations

1 site
  • University Health System Texas Diabetic Institute
    San Antonio, Texas 78207, United States
08

References and documents

Individual participant data

Plan to share: Yes — The deidentified quantitative data from the 15 participants such as demographics and clinical data could be shared upon request from the applicant after the study findings have been published in peer-reviewed journals. The biospecimen collected at the senior center will be transported to the School of Nursing Biobehavioral Laboratory by the laboratory staff or the PI in a dry ice container on the same day of data collection.

Supporting information: Study protocol, Sap, Icf

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06173804
Lead sponsor
The University of Texas Health Science Center at San Antonio
Responsible party
Sponsor
First posted
Dec 18, 2023
Start date
Jul 22, 2024
Primary completion
May 23, 2025
Completion
Aug 1, 2025
Last update
Jun 23, 2026

Study contacts

Yan Du, PhD, MPH
principal investigator · The University of Texas Health Science Center at San Antonio

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion